Malokhat Palvannazirovna Oltieva
Research Subjects
Research Interests
Malokhat Palvannazirovna Oltieva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dilfuza Abdullaevna Alieva
Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health Protection, Tashkent, Uzbekistan
1 shared publication - Erkin Isakovich Musabaev
Research Institute of Virology, Tashkent, Uzbekistan
1 shared publication - Iroda Pulatovna Sharipova
Research Institute of Virology, 7a, Yangi shahar, Yunus Abad, Tashkent, 100194, Uzbekistan
1 shared publication - Jasur Ravshanovich Juraev
Department of Preventive Service, Kyoto University , Kyoto
1 shared publication - Khasanjon Kobiljon Ugli Odilov
Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan
1 shared publication - Mirzarakhim Mirzakhakimovich Baynazarov
Department of Treatment Management, Ministry of Health of Uzbekistan , Tashkent, Uzbekistan
1 shared publication
Latest Publications
- Open Access
- 16 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1721
Epidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.
- 16 December 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1721
Open AccessEpidemiology of high-risk HPV in Uzbekistan among 44,000 women – genotypes, risk profiles and screening needs in Uzbekistan
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.